Properly Valuing Investment in the Development of Gene Replacement Therapy

12 Pages Posted: 8 May 2019

See all articles by Ike Brannon

Ike Brannon

The Jack Kemp Foundation

Anthony T. Lo Sasso

University of Illinois at Chicago - School of Public Health

Date Written: March 2019

Abstract

Gene Therapy represents a dramatically different approach to the disease treatment, promising complete cures rather than the management of chronic illnesses. Because of this the standard payment models used by insurance markets may not work effectively, leading to moral hazard problems and a potential under-investment in such treatments.

Keywords: drug prices, insurance, cost-benefit analysis

JEL Classification: I11, I13

Suggested Citation

Brannon, Ike and Lo Sasso, Anthony T., Properly Valuing Investment in the Development of Gene Replacement Therapy (March 2019). Available at SSRN: https://ssrn.com/abstract=3373135 or http://dx.doi.org/10.2139/ssrn.3373135

Ike Brannon (Contact Author)

The Jack Kemp Foundation ( email )

1200 New Hampshire Avenue N.W.
suite 800
Washington, DC 20036
United States

Anthony T. Lo Sasso

University of Illinois at Chicago - School of Public Health ( email )

1603 West Taylor Street
Chicago, IL 60612
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
35
Abstract Views
694
PlumX Metrics